TGen and HonorHealth initiate COVID-19 combination therapy of atovaquone and azithromycin

(The Translational Genomics Research Institute) The HonorHealth Research Institute and HonorHealth announced today the successful enrollment on a novel combination of atovaquone and azithromycin in patients with moderate-to-severe COVID-19 infection. The clinical trial, conducted in collaboration with the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, is funded as an investigator-initiated clinical trial by HonorHealth Research Institute.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news